Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
US patent 0337024, Allison Coffin, Joseph Harding, Leen Kawas, Phillip Uribe, "Novel Lead Compound for Otoprotection: Targeting HGF Signaling with Dihexa", issued 2015-11-26 "Dihexa" (PDF)
Unlike bisphosphonates, which work by slowing bone loss, teriparatide is a true anabolic agent
Key Components & Benefits 1
Increased FOXO4 expression correlates with enhanced proteasomal activity, leading to a reduction in the accumulation of damaged proteins, particularly in cardiovascular tissue
US$ 24.52
US$ 22.53
US$ 27.36
US$ 29.41
US$ 28.19
